Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ARID1A deficiency Hepatocellular Carcinoma

To uncover therapeutic strategies for ARID1A deficient HCC, we performed genome-scale CRISPR–Cas9 based synthetic lethality screens using ARID1A deficiency HCC cellular model Overall design: Briefy, Cas9 stably expressed cells (~5000-fold library coverage in each group) were infected withThe Toronto human knockout pooled (TKOv3) lentiviral library at a low MOI (0.2~0.3) and selected for 3 days with 2~5 ug/ml puromycin. A part of these transfected cells was harvested at baseline (T0), the rest of cells allowed to grow for three weeks and collected(T21).